GlassScriptPhysician profile
Shehetaj Abdurrahim
NPI 1437188372
$4,002.35
in general payments reported to CMS, 2019-2025
25 companies · $777 in 2025
The $777 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $999 · 2020: $555 · 2021: $377 · 2022: $365 · 2023: $469 · 2024: $461 · 2025: $777.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,682 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,681.65 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $829.24 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $533.90 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $331.19 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.90 | 2019-2025 | Jardiance |
| Abbott Laboratories | $221.74 | 2020-2025 | Freestyle Libre |
| Amgen INC. | $204.23 | 2019-2025 | Repatha, Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $143.05 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $142.96 | 2021-2025 | |
| Currax Pharmaceuticals LLC | $142.30 | 2019-2024 | Nexletol, Contrave |
| Pfizer INC. | $139.28 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $133.76 | 2019-2021 | |
| Astellas Pharma US INC | $132.06 | 2020-2024 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $109.64 | 2020-2021 | |
| Allergan, INC. | $109.12 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $98.71 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $92.67 | 2025 | Gemtesa |
| Dexcom, INC. | $77.55 | 2021-2024 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $75.62 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Mannkind Corporation | $69.16 | 2019 | |
| Janssen Pharmaceuticals, INC | $57.11 | 2019-2021 | |
| Shield Therapeutics INC | $45.91 | 2025 | |
| Phathom Pharmaceuticals, INC. | $20.97 | 2024 | Voquezna |
| Lifescan, INC. | $16.30 | 2023 | |
| Abbvie INC. | $14.69 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shehetaj Abdurrahim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.